OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase II study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676).

HTML

Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2014.32.4_suppl.305
Authors: Andrea Necchi, Patrizia Giannatempo, Luigi Mariani, Emanuela Fina, Nicola Nicolai, Marzia Pennati, Nadia Zaffaroni, Elena Farè, Luigi Piva, Davide Biasoni, Mario Catanzaro, Tullio Torelli, Silvia Stagni, Massimo Maffezzini, Maurizio Colecchia, Biagio Paolini, Vera Cappelletti, Maria Grazia Daidone, Alessandro M. Gianni, Roberto Salvioni
Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan
Language: English

Topic: Bladder and Urothelial Cancer Treatments
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Keywords: neoadjuvant chemotherapy, muscle-invasive bladder cancer, urothelial carcinoma, sorafenib, cisplatin, gemcitabine, pathological complete response, radical cystectomy, vascular endothelial growth factor, circulating tumor cells, biomarkers, hand-foot syndrome, hematologic toxicity, treatment toxicity, disease-free survival, recurrence-free survival, progression-free survival
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2591076216
Cites:
Cited by: 1
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms